fucoxanthin and Colitis

Extracellular vesicles (EVs) are very attractive as carriers of active components due to their good immunological and their ability to penetrate the physiological barrier that synthetic delivery carriers cannot penetrate. However, the low secretion capacity of EVs limited its widespread adoption, let alone the lower yield of EVs loaded with active components. Here, we report a large-scale engineering preparation strategy of synthetic probiotic membrane vesicles for encapsulating fucoxanthin (FX-MVs), an intervention for colitis. Compared with the EVs naturally secreted by probiotics, the engineering membrane vesicles showed a 150-fold yield and richer protein. Moreover, FX-MVs improved the gastrointestinal stability of fucoxanthin and inhibited H

Topics: Colitis; Cytokines; Humans; Hydrogen Peroxide; Probiotics

Topics: Animals; Azoxymethane; Carcinogenesis; Colitis; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Humans; Mice; Xanthophylls